...
首页> 外文期刊>Scientific reports. >CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
【24h】

CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models

机译:CMScaller:R包,用于大肠癌临床前模型的共有分子亚型分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Colorectal cancers (CRCs) can be divided into four gene expression-based biologically distinct consensus molecular subtypes (CMS). This classification provides a potential framework for stratified treatment, but to identify novel CMS-drug associations, translation of the subtypes to pre-clinical models is essential. The currently available classifier is dependent on gene expression signals from the immune and stromal compartments of tumors and fails to identify the poor-prognostic CMS4-mesenchymal group in immortalized cell lines, patient-derived organoids and xenografts. To address this, we present a novel CMS classifier based on a filtered set of cancer cell-intrinsic, subtype-enriched gene expression markers. This new classifier, referred to as CMScaller, recapitulated the subtypes in both in vitro and in vivo models (551?in total). Importantly, by analyzing public drug response data from patient-derived xenografts and cell lines, we show that the subtypes are predictive of response to standard CRC drugs. CMScaller is available as an R package.
机译:大肠癌(CRC)可以分为四种基于基因表达的生物学上不同的共有分子亚型(CMS)。这种分类为分层治疗提供了潜在的框架,但是要确定新型的CMS-药物关联,将亚型转化为临床前模型至关重要。目前可用的分类器依赖于肿瘤免疫和基质区隔的基因表达信号,并且无法鉴定永生化​​细胞系,患者来源的类器官和异种移植物中预后较差的CMS4-间质组织。为了解决这个问题,我们提出了一种新的CMS分类器,它基于一组过滤的癌细胞固有的,亚型丰富的基因表达标记。这个新的分类器称为CMScaller,在体外和体内模型中概括了亚型(总计551?)。重要的是,通过分析来自患者异种移植物和细胞系的公共药物反应数据,我们表明亚型可预测对标准CRC药物的反应。 CMScaller作为R软件包提供。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号